It’s no secret that the only cannabis available for official use on research is provided by the University of Mississippi and NIDA, which is notoriously low in quality. The lawsuit also states that this marijuana is unfit for research because of “poor quality, unstable supply, and limited variability that in no way emulates the types of cannabis currently available through either state-regulated markets or informal markets where regulated supply is unavailable.” What makes it worse is that this cannabis is only allowed for research and not to be sold commercially, which means that it can’t be used for Phase 3 studies of the FDA, required under the Good Manufacturing Processes.
This column originally appeared in Cultivated, a cannabis industry newsletter. Subscribe here. You know the…
The DEA has opened a new registration process for state-licensed medical cannabis manufacturers, distributors and…
This November gathering will bring psychedelic education into conversation with music, visual art, comedy, philosophy,…
Ten p.m. on a Glendale balcony, two floors above the theater that just screened the…
We analyzed seven different 2026 rankings to find the true top 10 cannabis strains in…
A land-rooted look at the growers reshaping cannabis through living soil, ecological intelligence and regenerative…